258 related articles for article (PubMed ID: 24669373)
1. Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.
Lin CJ; Chen SN; Hwang JF; Yang CM
J Pediatr Ophthalmol Strabismus; 2013; 50(6):356-62. PubMed ID: 24669373
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
3. Visual outcomes after treatment in pediatric patients with Coats' disease.
Chiu HH; Wan MJ; Kertes PJ; Muni RH; Lam WC
Can J Ophthalmol; 2019 Dec; 54(6):647-652. PubMed ID: 31836093
[TBL] [Abstract][Full Text] [Related]
4. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats' disease.
Yang Q; Wei W; Shi X; Yang L
Acta Ophthalmol; 2016 Jun; 94(4):401-6. PubMed ID: 27150442
[TBL] [Abstract][Full Text] [Related]
5. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat's disease.
Li S; Deng G; Liu J; Ma Y; Lu H
BMC Ophthalmol; 2017 May; 17(1):76. PubMed ID: 28532448
[TBL] [Abstract][Full Text] [Related]
6. Risk of Tractional Retinal Detachment Following Intravitreal Bevacizumab Along with Subretinal Fluid Drainage and Cryotherapy for Stage 3B Coats' Disease.
Bhat V; D'Souza P; Shah PK; Narendran V
Middle East Afr J Ophthalmol; 2016; 23(2):208-11. PubMed ID: 27162454
[TBL] [Abstract][Full Text] [Related]
7. The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.
Zheng XX; Jiang YR
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):35-42. PubMed ID: 23873253
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.
Zhang L; Ke Y; Wang W; Shi X; Hei K; Li X
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1339-1346. PubMed ID: 29549425
[TBL] [Abstract][Full Text] [Related]
9. Treatment of stage 3 Coats' disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach.
Cai X; Zhao P; Zhang Q; Jin H
Graefes Arch Clin Exp Ophthalmol; 2015 Jul; 253(7):999-1004. PubMed ID: 25794987
[TBL] [Abstract][Full Text] [Related]
10. Successful use of intravitreal bevacizumab and pascal laser photocoagulation in the management of adult Coats' disease.
Raoof N; Quhill F
Middle East Afr J Ophthalmol; 2013; 20(3):256-8. PubMed ID: 24014992
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment for Coats' disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases.
Kodama A; Sugioka K; Kusaka S; Matsumoto C; Shimomura Y
BMC Ophthalmol; 2014 Mar; 14():36. PubMed ID: 24666524
[TBL] [Abstract][Full Text] [Related]
13. A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats' disease.
Wang KY; Cheng CK
J Ocul Pharmacol Ther; 2011 Oct; 27(5):525-30. PubMed ID: 21951171
[TBL] [Abstract][Full Text] [Related]
14. Management of stage 3B Coats disease: presentation of a combined treatment modality and long-term follow-up.
Liang T; Peng J; Zhang Q; Zhu X; Xu Y; Zhao P
Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2031-2038. PubMed ID: 32474693
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant anti-VEGF therapy in Coats' disease].
Fiorentzis M; Stavridis E; Seitz B; Viestenz A
Ophthalmologe; 2015 May; 112(5):451-4. PubMed ID: 25134462
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.
Park S; Cho HJ; Lee DW; Kim CG; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1511-1517. PubMed ID: 26631136
[TBL] [Abstract][Full Text] [Related]
17. Coats' disease: characteristics, management, outcome, and scleral external drainage with anterior chamber maintainer for stage 3b disease.
Yousef YA; ElRimawi AH; Nazzal RM; Qaroot AF; AlAref AH; Mohammad M; Abureesh O; Rejdak R; Nowomiejska K; Avitabile T; Toro MD; AlNawaiseh I
Medicine (Baltimore); 2020 Apr; 99(16):e19623. PubMed ID: 32311932
[TBL] [Abstract][Full Text] [Related]
18. TRANSCLERAL DRAINAGE OF SUBRETINAL FLUID, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, AND WIDE-FIELD IMAGING-GUIDED LASER IN COATS EXUDATIVE RETINAL DETACHMENT.
Stanga PE; Jaberansari H; Bindra MS; Gil-Martinez M; Biswas S
Retina; 2016 Jan; 36(1):156-62. PubMed ID: 26355946
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Visual Outcomes in Coats' Disease: A 20-Year Experience.
Ong SS; Buckley EG; McCuen BW; Jaffe GJ; Postel EA; Mahmoud TH; Stinnett SS; Toth CA; Vajzovic L; Mruthyunjaya P
Ophthalmology; 2017 Sep; 124(9):1368-1376. PubMed ID: 28461016
[TBL] [Abstract][Full Text] [Related]
20. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
He YG; Wang H; Zhao B; Lee J; Bahl D; McCluskey J
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1519-21. PubMed ID: 20379736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]